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Introduction: The discovery that somatic mutations in the epider-
mal growth factor receptor (EGFR) gene are associated with sensi-
tivity to the EGFR tyrosine kinase inhibitors (TKIs) in lung adeno-
carcinomas, whereas Kras mutations are associated with resistance,
has generated excitement among both clinicians and researchers
studying non-small cell lung cancer (NSCLC). Mutational analysis
may soon be very useful in choosing among a wide range of targeted
therapies to individualize treatment to tumor characteristics. This
analysis would be even more useful in patients with advanced
NSCLC, in whom cytological specimens are often the only material
available.
Methods: We analyzed 23 archived cytologic specimens of ad-
vanced/metastatic lung adenocarcinomas for mutations in EGFR
exons 18 to 21, and Kras exon 2.
Results: Our data show that our cytological specimens were per-
fectly adequate for the molecular analysis of EGFR and Kras
mutations. EGFR TK domain mutations were found in three cases
(13.04%) and were associated with both female gender (p  0.02)
and a nonsmoking history (p  0.008).
Moreover, we explored the relationship between EGFR mutation
status and the presence of Kras mutations. Kras mutations involving
codon 12 in exon 2 were found in 5 (21.73%) of the 23 adenocar-
cinomas and were associated, where known, with smoking habits.
We never found EGFR alterations in tumors with Kras mutations.
Conclusions: Our results provide oncologists with a highly accurate
laboratory method to identify biological predictors of the efficacy of
different therapies, and they may have an important impact on
clinical practice. This method may be particularly useful in patients
with advanced/metastatic NSCLC.
Key Words: Cytology, Non-small cell lung cancer, Epidermal
growth factor receptor, Kras.
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The discovery that somatic mutations in the epidermalgrowth factor receptor (EGFR) gene in lung adenocarci-
nomas are associated with sensitivity to the EGFR tyrosine
kinase inhibitors (TKI) gefitinib1,2 and erlotinib,3 whereas
Kras mutations are associated with resistance to TKIs,4–6 has
generated excitement among clinicians and researchers study-
ing non-small cell lung cancer (NSCLC). Mutational analysis
should soon be very useful to clinicians in choosing among
the wide range of targeted therapies that can be implemented
for individual patients. For patients with advanced/metastatic
lung cancer in whom cytological specimens, such as fine-
needle aspirations, sputum, and bronchial washing or brush-
ing are often the only materials available, mutational analysis
should be particularly useful. In our study, we explored the
feasibility of performing mutational analysis on diagnostic
cytological specimens of lung adenocarcinoma, and we dem-
onstrated that all of our samples were perfectly adequate for
molecular analysis of both EGFR and Kras mutations by an
automated sequencing method.
MATERIALS AND METHODS
Patient and Specimen Characteristics
We analyzed 23 archived cytological specimens, which
were collected at our institute from NSCLC patients from
April 2005 to April 2006.
Samples were obtained as follows: 17 out of 23 by
fine-needle aspiration, 1 by sputum, 4 by bronchial washing,
and 1 by bronchial brushing. Specimens from sputum and
bronchial brushing were processed by the liquid-based, thin-
layer cytology Thin Prep 2000 method (Cytyc Co., Marlbor-
ough, MA). The material was fixed with the hemolytic and
preservative solution Cytolit (Cytyc Co.). The cells were spun
at 1500 rpm, and then the sediment was transferred to the
Preservcyt (Cytyc Co.) solution to be processed with the
T2000 automated processor, according to the manufacturer’s
recommendations. The resulting slide was fixed in 95%
ethanol and was stained with Papanicolaou.
The slides of all of the specimens were incubated in
xylene overnight to remove the coverslip, and then they were
washed in 100% and 70% ethanol. The cells were microdis-
sected, using a 25-gauge needle on a syringe as a microdis-
secting tool. While viewing the tissue through the micro-
scope, the cell population of interest was gently scraped with
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the needle. The tip of the needle with the procured tissue
fragments was carefully placed into a small PCR tube con-
taining the appropriate buffer. Gentle shaking of the tube
ensured that the tissue detached from the tip of the needle.
PCR for EGFR Exons 18 to 21
Total DNA was extracted from the specimens, using a
standard acid–guanidium–phenolchloroform method. DNA
extraction was then performed, using a spin column proce-
dure (QIAamp Tissue Kit, Qiagen).
The eluted DNA was used as template in a standard
20-l PCR reaction mixture consisting of 20 mM Tris-HCl,
50 mM KCl, 1.5 mM MgCl2 (pH 8.3), 0.2 mM deoxynucleo-
side triphosphate, 8 pmol each of sense and antisense primer,
and 2.5 units of AmpliTaq Gold (Applied Biosystems). Prim-
ers used for the amplification were as follows:
for exon 18,
5=-ACCCTTGTCTCTGTGTTCTTGTCC-3=
5=-AGACCATGAGAGGCCCTGC-3=;
for exon 19,
5=-GCACCATCTCACAATTGCCAGTTA-3=
5=-GAGGTTCAGAGCCATGGACCC-3=;
for exon 20,
5=-CACACTGACGTGCCTCTCCCTCCC-3=
5=-CTCCCCTCCCCGTATCTCCCTTCC-3=;
and for exon 21,
5=-CCATGATGATCTGTCCCTCACA-3=
5=-AGGAAAATGCTGGCTGACCTAAAG-3=.
PCR product sizes for EGFR exons 18, 19, 20, and 21
were 207, 194, 247, and 235 bp, respectively. Because all of
the primers had similar melting temperatures, the same PCR
conditions were used to simultaneously amplify all four
exons (in separated reaction tubes): after initial denaturation
at 94°C (7 minutes), there were 35 cycles of denaturation at
94°C for 60 seconds, annealing at 58°C for 60 seconds, and
synthesis at 72°C for 60 seconds, followed by a final exten-
sion at 72°C for 7 minutes. As a negative control, the DNA
template was omitted from the reaction. The amplification
products were separated on 1.5% agarose gels and visualized
by ethidium–bromide staining.
For the detection of mutations, PCR products were puri-
fied with ExoSAP-IT (Amersham Biosciences) and sequenced
using a cyclic sequencing kit (ALFexpress II, Amersham Bio-
sciences), according to the manufacturer’s recommendations.
Mutagenic PCR for Kras Exon 2
DNA previously extracted was amplified by a muta-
genic PCR assay. We used a mismatched upstream primer for
codon 12 amplification and a mismatched downstream primer
for codon 13 amplification, which introduced a BstNI and a
HaeIII restriction site, respectively, in the wild-type allele.
The primers used were as follows:
Kras/12 (sense)
5=-ACTGAATATAAACTTGTGGTAGTTGGACCT-3=
(nt 99–128)
and (antisense)
5=-CTGTATCAAAGAATGGTCCTGCACCAGTA-3= (nt
232–260),
Kras/13 (sense)
5=-GTACTGGTGGAGTATTTGATAGTGTATTAA-3=
(nt 1–30)
and (antisense)
5=-GTATCGTCAAGGCACTCTTGCCTAGG-3= (nt
134–159).
The underlined bases represent mismatches.
RFLP Analysis (Restriction Fragment
Polymorphism Analysis)
BstNI digestion of the wild-type codon 12 allele yielded
two bands of 133 and 29 bp, whereas the mutant remained
intact (162 bp). HaeIII digestion of the wild-type codon 13
allele yielded fragments of 85, 48, and 26 bp, whereas the
mutant yielded only two fragments of 85 and 74 bp. (A
constant HaeIII site at nucleotide 85 yielded an 85-bp frag-
ment in all samples).
Statistical Analysis
All statistical analyses were carried out using Statistica
software (Stat-soft). A chi-square test was used to analyze the
associations between the different variables. The a priori
level of significance was set at a p value of less than 0.05.
RESULTS
Patient and Specimen Characteristics
There were 14 men (60.9%) and 9 women (39.1%),
with ages at diagnosis ranging from 44 to 77 years (mean age
62.3 years, median 64 years). Smoking habits were known for
14 of the 23 patients: there were 5 nonsmokers (35.7%, all
women) and 9 smokers (64.3%, 7 men and 2 women).
Cytologic type of the adenocarcinoma was determined ac-
cording to WHO criteria7; for three cases, BAC pattern was
predominant. Advanced pathologic staging of lung cancers
was determined according to the revised International System
for Staging Lung Cancer8 for four cases; in the other patients,
it was not possible to perform staging, because the cytolog-
ical specimen represented the only diagnostic tool.
All twenty-three cytological specimens (17 fine-needle
aspirations, 1 sputum in thin-prep, 4 bronchial washings, and
1 bronchial brushing in thin-prep) were informative, contain-
ing enough cells to isolate a sufficient amount of DNA for
mutational analysis. Also, liquid-base cytology seems to be a
reliable cytologic method for this molecular approach.
EGFR Mutations
EGFR TK domain mutations were found in three cases
(13.04%). Of those three mutations, two were in-frame dele-
tions in exon 19, and one was a point mutation in exon 20.
The in-frame deletions in exon 19 involved five codons,
E746–A750, from nucleotide 2235 to 2249; the mutation in
exon 20 resulted in a threonine-to-methionine amino acid
change at position 790 (T790M) in the kinase domain. All
three cases were from women who had never smoked (Table
1). Representative nucleotide sequences of the EGFR muta-
tions are shown in Figure 1.
We analyzed the relationship between EGFR mutations
and clinicopathologic features of adenocarcinomas (Table 2).
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EGFR mutations in adenocarcinomas were associated with
both female gender (p  0.02) and with smoking habits (p 
0.008).
Kras Mutations
Examples of representative RFLP products for the Kras
mutational analysis are shown in Figure 2.
Kras mutations were not found in adenocarcinomas
with EGFR mutations (Table 2), suggesting a mutually ex-
clusive relationship.
Kras mutations were found in 5 (21.73%) of the 23
adenocarcinomas, involving codon 12 in exon 2 (Table 3).
DISCUSSION
Accumulating evidence suggests that gefitinib provides
a survival benefit to patients with NSCLCs harboring EGFR
mutations. Therefore, screening for EGFR mutations in all
advanced NSCLC patients is expected to become a routine
procedure. To examine a large number of samples, and to
deal with the variety of clinical settings in which the samples
are taken, an EGFR mutation test that is sensitive and inte-
grated into the standard procedures for cancer diagnosis is
needed. This report examines an approach to mutational
analysis of a variety of cytological specimens (fine-needle
aspirations, sputum in thin-prep, bronchial washing, and
A. EGFR Exon 19
EGFR protein 744       I       K       E      L        R       E      A T       S    752
EGFR gene         2230   ATC AAG GAA TTA AGA GAA GCA ACA TCT 2256
Case 1, 2              ATC AA -------------------------------------A ACA TCT
Wild type
Case 1, 2
B. EGFR Exon 20
EGFR protein 788      L      I         T      Q       L    792
EGFR gene         2362  CTC ATC ACG CAG CTC 2376
Case 23               CTC ATC ATG CAG CTC
Wild type
Case 23
FIGURE 1. Mutations in the EGFR gene in non-small cell lung cancer. (A) One pattern of an in-frame deletion in EGFR exon
19, and its representative electropherogram. (B) T790M mutation in EGFR exon 20.
TABLE 1. Genetic Alterations in the Kinase Domain of the
EGFR Gene (Exons 18–21)
Case No. Histology Sex
Age
(yr)
Smoking
Status Exon
Aminoacidic
Alteration
1 Adeno F 44 Never 19 E746 A750 del
2 BAC F 57 Never 19 E746 A750 del
23 Adeno F 45 Never 20 T790M
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bronchial brushing in thin-prep) by scraping cells off of the
diagnostic glass slide without destaining processes, giving
faster results. Information about EGFR mutations is, there-
fore, available at the time when the oncologists determine the
treatment regimen for each patient, and we have found this
information to be very useful. Moreover, our test uses diag-
nostic samples, and, therefore, patients do not need to un-
dergo additional procedures. Our method is also based on a
simple, widely available technique of automated sequencing;
therefore, our analysis is easily integrated into clinical prac-
tice and is expected to help medical specialists use the latest
research results to select the optimal treatment strategy for
lung cancer patients. Because EGFR mutations in lung can-
cers were limited to the first four exons (exons 18–21) of the
TK domain in previous studies,1,2,9,10–12 we searched for
mutations in these four exons in our 23 cytological specimens
of advanced lung adenocarcinoma. EGFR TK domain muta-
tions were found in three cases (13.04%); the frequency of
EGFR mutations was within the range already reported in
other studies.13 Deletions in exon 19, targeting a five-codon
region (codons 746–750), as well as a mutation in exon 20
(T790M), have both been reported previously.10–12,14 Most
studies have shown a significant association of EGFR muta-
tions, particularly exon 19 deletions, and response to
TKIs.15–24 On the other hand, the T790M substitution has
been reported in progressive lesions after gefitinib or erlotinib
therapy.25,26 Our patient (number 23) was a nonsmoking
female with a stage IV adenocarcinoma of the lung, who
showed progression of the disease after 14 months of therapy
with gefitinib (250 mg/day) as the first-line therapy; the
T790M mutation was found in the biopsy performed in this
patient after the treatment with the EGFR-TKI. Recent stud-
ies also showed a differential impact on survival of different
EGFR mutations.27–29
Consistent with previous studies,1,2,9–12,14,30 EGFR mu-
tations were associated with both female gender and a non-
smoking history.
Moreover, we explored the relationship between EGFR
mutational status and the presence of Kras mutations. Kras is
a critical downstream effector of the EGFR pathway, which
has been found to be mutated in about 15% to 30% of lung
adenocarcinomas.12,31 Activating mutations of Kras usually
occur in codons 12 and 13 of exon 232,33 and have been
reported to be associated with intrinsic TKI resistance.5
Mutations in Kras are commonly associated with a history of
tobacco smoke exposure,31 and several studies have shown
that EGFR-sensitizing mutations and Kras mutations are
mutually exclusive.4,5,10–12,28,32,33 Consistent with all previ-
ous studies, in our series of lung adenocarcinomas, Kras
mutations involving codon 12 in exon 2 were found in 5
(21.73%) of the 23 adenocarcinomas and were associated,
where known, with smoking habits; we never found EGFR
alterations in tumors with Kras mutations. In conclusion, we
have demonstrated the feasibility of performing mutational
analysis on archived cytological specimens. This may be
especially important for metastatic NSCLC patients, where
cytologic material frequently is all that is available. Testing
of EGFR and Kras mutations is likely to become indispens-
able in selecting the best treatment options for individual
patients with lung cancer.
TABLE 2. EGFR Mutations in 23 Cytological Specimens of
Advanced Lung Adenocarcinoma
Variables n
EGFR Status
pwt mut
Age (yr)
65.5 12 9 3 0.07
65.5 11 11 0
Sex
Male 14 14 0 0.02
Female 9 6 3
Smoking status
Nonsmokers 5 2 3 0.008
Longtime smokers 9 9 0
Kras status
Wild type 18 15 3 0.32
Mutated 5 5 0
A. Mutagenic PCR
Kras codon 12
B.     RFLP Analysis
Kras codon 12
162 bp
162 bp
133 bp
1      2      3     4    Cn M
1       2       3      4      M
FIGURE 2. Mutations in the Kras gene in non-small cell
lung cancer. (A) Gel electrophoresis of mutagenic PCR prod-
ucts for codon 12 of Kras. Lanes 1 through 3, NSCLC sam-
ples; lane 4, control sample; Cn, negative control (with no
DNA added); M, molecular weight marker (100 bp). (B) Gel
electrophoresis of PCR products digested with restriction en-
zyme BstNI. Lane 1, homozygous sample for codon 12 mu-
tation (uncut PCR product of 162bp); lane 2, heterozygous
sample (bands at 162 and 133bp); lane 3, homozygous nor-
mal sample (band at 133bp); lane 4, homozygous normal
control; M, molecular weight marker (50 bp).
TABLE 3. Kras Alterations
Case No. Histology Sex Age (yr) Smoking Status Codon
3 Adeno F 52 Unknown 12
7 Adeno F 77 Current 12
12 Adeno M 76 Current 12
14 Adeno M 68 Unknown 12
19 Adeno M 68 Current 12
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